KAYLA CRAWFORD: Open Payments
NPI 1073168837 · DRASCO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$627 in 39 payments from 12 companies in 2025. Trend: 2023 $361 · 2024 $570 · 2025 $627
Food & beverage: $627
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $185 |
| ABBVIE INC. | 16 | $158 |
| AstraZeneca Pharmaceuticals LP | 2 | $57 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $54 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Lilly USA, LLC | 2 | $31 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Novo Nordisk Inc | 1 | $23 |
| Lundbeck LLC | 1 | $18 |
| Verona Pharma, Inc. | 1 | $16 |
Products named: REXULTI, VRAYLAR, BREZTRI, CAPLYTA, TRELEGY ELLIPTA, MOUNJARO, COBENFY, Ozempic.
Industry payments across AR — which companies pay providers there.
